InMed Pharmaceuticals Inc. (INM) Misses Q3 EPS by 194c
Tweet
Share
E-mailGet Alerts INM Hot Sheet
Join SI Premium – FREE
InMed Pharmaceuticals Inc. (NASDAQ: INM) reported Q3 EPS of ($1.94), $1.94 worse than the analyst estimate of $0.00. Revenue for the quarter came in at $1.26 million versus the consensus estimate of $0 .
For earnings history and earnings-related data on InMed Pharmaceuticals Inc. (INM) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- MaxLinear (MXL) Tops Q2 EPS by 2c; Offers Guidance
- Glacier Bancorp (GBCI) Tops Q2 EPS by 1c, Misses on Revenue
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
